Maxim Group Thinks SELLAS Life Sciences Group Inc’s Stock is Going to Recover


In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS), with a price target of $5. The company’s shares opened today at $1.69, close to its 52-week low of $0.80.

McCarthy said:

“Sellas announced complete enrollment of the phase 2 trial (N=100) of nelipepimut-S vaccine (NeuVax, NPS) combined with Herceptin (traztuzumab) in HER2 high-expressers. Data from the trial is expected to readout in 4Q19.”

According to TipRanks.com, McCarthy is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -2.4% and a 32.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

Currently, the analyst consensus on SELLAS Life Sciences Group Inc is a Moderate Buy with an average price target of $9, representing a 432.5% upside. In a report issued on November 15, Oppenheimer also assigned a Buy rating to the stock with a $13 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $12.01 and a one-year low of $0.80. Currently, SELLAS Life Sciences Group Inc has an average volume of 2.02M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts